Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Union Budget
Budget 2011-2012 Home
Industry Expectations - Budget 2011-2012
Industry Reactions - Budget 2011-2012
Budget 2010-2011
Budget 2010-2011 Home
Industry Expectations - Budget 2010-2011
Industry Reactions - Budget 2010-2011
Contributor's Corner
Bonanza Portfolio
Hemant K Gupta
Krish Bhatt
S A A R T H I
Trinity Investments
Exchange Information
BSE 2009 Holidays
NSE 2009 Holidays
Investor Guide
Depository & Dematerialisation
Grievance Redressal
Investor Guide
SEBI
Trading of Securities
Transfer of Securities
Your Rights
Budget 2009-2010
Budget 2009-2010 Home
Industry Expectations - Budget 2009-2010
Industry Reactions - Budget 2009-2010
Interim Budget 2009-2010 Home
Industry Expectations - Interim Budget 2009
Budget 2008-2009
Railway Budget 2008-2009
Industry Expectations - Budget 2008
Union Budget 2008-2009
Highlights of Budget 2008-2009
Summary of Budget 2008-2009
Industry Reactions - Budget 2008
IPOs
Current IPOs
Past IPOs
IPO Subscription
Mutual Funds
Gold Exchange Traded Fund
MF Unique Holding
Forthcoming Dividends
ELSS Schemes Comparison
Tax Plans
New Fund Offers
Research
Arbitrages
Equity
Market Whispers
Tax Planning
Home
Equity Linked Savings Scheme
Post Office MIS
9% GOI Senior Citizens Savings Scheme
8% Savings (Taxable) Bonds
Kisan Vikas Patra
National Savings Certificate
Public Provident Fund
Research

| More

Crisil - Panacea Biotec Ltd - Independent Equity Research Report

Posted On: 2011-12-14 22:00:23

Panacea Biotec Ltd (Panacea) has so far witnessed strong business momentum in both combination vaccines and formulations. While demand continues to gain traction, Panacea's growth will likely hit a roadblock as WHO (World Health Organisation) has de-listed its combination vaccines, including the high-margin EasyFive, from the pre-qualified list of vaccines. We have lowered our FY12 estimates to account for the loss in business. However, we maintain our fundamental grade of 3/5 as we believe that the problem is likely to be a short term one and the long-term business prospects look optimistic. Growth momentum in combination vaccines stalled in the near term.

Combination vaccines had been witnessing strong traction in demand, apparent from EasyFive's ~220% y-o-y revenue growth in FY11. WHO has recently delisted the product because of quality management issues. Consequently, we expect growth to get stalled as UNICEF is the largest customer. However, management is expecting to fix the issue in 3-4 months. We expect the supplies to resume by Q1FY13 and remain optimistic on the long-term growth prospects of combination vaccines.

Expect gradual de-growth in polio vaccine sales

Polio vaccine sales declined by ~17% y-o-y in FY11 largely due to: 1) decline in procurement by UNICEF because of increase in polio eradication globally, and 2) Indian government now procuring vaccines on need basis only. However, we view limited near-term risk to demand for polio vaccines given the significant number of cases still recorded globally. Going ahead, we expect sales to de-grow, but on a more gradual curve.

New products and geographic expansion to benefit formulations

Formulation sales grew ~24% y-o-y in FY11, largely driven by strong traction in its existing products and entries into new markets. Exports grew by ~110% driven by strong demand for Tacrolimus and Cyclosporine in Latin America. Going ahead, we believe that catalysts such as expected approval in regulated markets and launch of new products will continue to crank the growth engine.

Revenue growth and profitability curve to cave-in in FY12

We expect FY12 revenue to decline ~25% y-o-y to ~Rs 8,650 mn and EBITDA margin to contract by 1,440 bps to ~8% on loss of EasyFive sales to UNICEF and higher raw material costs driven by unfavourable forex movement. We expect revenue and margins to improve to ~Rs 11,934 mn and 19.0% in FY13.

Valuations the current price has 'upside'

Based on our new estimates, we arrive at a fair value of Rs 100 per share. We propose a valuation grade of 4/5, indicating that the market price has upside from the current levels.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Views on New FDI norms for Pharmaceuticals: Angel Broking
Views on Zydus Cadila- Acquires two ANDA's form Teva: Angel Broking
Mahanagar Gas Limited - IPO Note - Angel Broking
Views on update of Infosys: Angel Broking
Tech Mahindra - 4QFY2016 Result Update - Angel Broking
Views on Lupin Ltd 4QFY2016 Results: Angel Broking
Views on Ramco Cements Ltd 4QFY2016 Results: Angel Broking
Views on Punjab National Bank 4QFY2016 Results: Angel Broking
Dr Reddy's Laboratories - 4QFY2016 Result Update - Angel Broking
Cadila Healthcare - 4QFY2016 Result Update - Angel Broking
Visaka Industries Ltd - 4QFY2016 Result Update - Angel Broking
ITC - 4QFY2016 Result Update - Angel Broking
Lupin Ltd - 4QFY2016 Result Update - Angel Broking
Views on Tech Mahindra Ltd 4QFY2016 Results: Angel Broking
Voltas Ltd - 4QFY2016 Result Update - Angel Broking
Views on Cipla Ltd 4QFY2016 Results: Angel Broking
Views on GlaxoSmithKline Pharmaceuticals Limited 4QFY2016 Results: Angel Broking
HSIL - 4QFY2016 Result Update - Angel Broking
National Buildings Construction Corporation Ltd - 4QFY2016 Result Update - Angel Broking
Views on Indoco Remedies Ltd 4QFY2016 Results: Angel Broking
Views on State Bank of India 4QFY2016 Results: Angel Broking
Garware Wall Ropes - 4QFY2016 Result Update - Angel Broking
Larsen and Toubro - 4QFY2016 Result Update - Angel Broking
Views on IPCA Laboratories Ltd 4QFY2016 Results: Angel Broking
Views on Aurobindo Pharma Ltd 4QFY2016 Results: Angel Broking
Views on Sun Pharmaceutical Industries Limited 4QFY2016 Results: Angel Broking
Views on Voltas Limited 4QFY2016 Results: Angel Broking
Views on National Building Construction Corporation 4QFY2016 Results: Angel Broking
RSWM Limited - Q4FY16 Result Update - Anand Rathi
Views on IL&FS Transportation Networks Ltd 4QFY2016 Results: Angel Broking
Views on MM Forgings Ltd. 4QFY2016 Results - Angel Broking
Ujjivan listing - CapitalVia Global Research
Dewan Housing Finance - 4QFY2016 Result Update - Angel Broking
Procter & Gamble Hygiene & Health Care - 3QFY2016 Result Update - Angel Broking
Sanofi India - 1QCY2016 Result Update - Angel Broking
Views on HDFC Ltd. 4QFY2016 Results: Angel Broking
Views on Alembic Pharmaceuticals Ltd 4QFY2016 Results: Angel Broking
Rallis India - 4QFY2016 Result Update - Angel Broking
Views on United Phosphorous Ltd 4QFY2016 Results: Angel Broking
Views on Sanofi India Ltd 1QCY2016 Results: Angel Broking
Views on ICICI Bank 4QFY2016 Results: Angel Broking
Views on ACC Ltd. 1QCY2016 Results: Angel Broking
Views on HCL Technologies Ltd 3QFY2016 Results: Angel Broking
Views on Elecon Engineering Company Ltd. 4QFY2016 Results: Angel Broking
Tata Consultancy Services - 4QFY2016 Result Update - Angel Broking
Views on Sadbhav Engineering Ltd. 4QFY2016 Results: Angel Broking
Views on Yes Bank 4QFY2016 Results: Angel Broking
Views on Rallis India Ltd 4QFY2016 Results: Angel Broking
Views on Axis Bank 4QFY2016 Results: Angel Broking
Views on Mahindra Lifespace Developers Ltd. 4QFY2016 Results: Angel Broking


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2014